The kinases have been intensely studied because of their involvement in regulating essential cellular activation of signaling cascades in response to extracellular and intracellular stimuli to control cell growth, proliferation, and survival. Recent cancer genomic sequencing studies have revealed that many more kinases contribute to tumor genesis and are potential targets for inhibitor drug development intervention. Herein we review recent results that have helped to unravel the indolin-2-ones underlying the conflicting roles of the kinase inhibition regulation. This review focuses on the potential of kinases as a chemotherapeutic target in cancer treatment and highlights important recent advances in the development of indolin-2-ones as kinase inhibitors.
Introduction
The kinases signify a large family of membrane-bound enzymes that play key roles in tumor growth, survival, and metastasis. Many kinases have been found to be closely involved in the processes leading to tumor cell proliferation and survival. Deregulation of kinase function has been implicated in other disorders, including neurological, immunological, metabolic and infectious disease. This has generated a great interest in the development of small molecule kinase inhibitors for the treatment of these disorders [1] . A number of small molecule kinase inhibitor like Sorafenib and Imatinib has been approved for the treatment of cancer. 3-Substituted indolin-2-ones have been reported in several literatures as potent and selective inhibitors of different kinases. Pyrrole-indoline-2-ones were among the first structures identified as kinase inhibitors and have been intensively studied for the inhibition of VEGFR, PDGFR α/β, c-kit, FLT3, and CSF1R [2] . Moreover the importance of indolin-2-one as kinase inhibitor is also reviewed by Underiner et al. [3] . The first compound of this type reaching the clinic was Sunitinib (Sutent; Pfizer) (Figure 1) , has been approved and marketed for the treatment of renal cell carcinoma and Imatinib resistant GIST [4] . This review provides an overview of the indolin-2-one based molecules approved by USFDA and compounds under clinical trials as RTKIs.
Indolin-2-Ones Drugs in Market
The search for synthetic inhibitors of protein kinases as anti-tumor drugs has been invigorated by the successful approval of a number of molecules that target tyrosine kinases. The indolin-2-one based Sunitinib is a smallmolecule inhibitor of multiple RTK involved in cancer, including VEGFR, PDGFR. It was approved by the USFDA for the treatment of GIST and advanced renalcell carcinoma in January 2006 and European Union approval in January 2007 [5] . Sunitinib is the first anticancer drug which received simultaneous FDA approval for two different indications. It has potent anti-angiogenic effects and direct anti-tumor activities due to the selective inhibition of VEGFR-1 (also known as FLT1), VEGFR-2 (also known as FLK1/KDR), VEGFR3 (also known as FLT4), PDGFRα, PDGFRβ, c-kit, FLT3, RET, and CSF1R.
Toceranib Phosphate [6] (Palladia) an orally bioavailable compound is similar to Sunitinib, exhibiting potent inhibitory activity against members of the split-kinase receptor family, including VEGFR, PDGFR, and Kit, and was therefore predicted to have both anti-angiogenic and direct anti-tumor activity. Toceranib phosphate (Figure 2 ) is a small molecule with an indolinone chemical structure and approved by USFDA for the treatment of canine cu- taneous (skin-based) mast cell tumors, a type of cancer responsible for about 1 out of 5 cases of canine skin tumors. The drug is approved to treat the tumors with or without regional lymph node involvement in June 2009. Toceranib an TKI and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor. In a random clinical trial study, Toceranib showed a statistically significant variation in tumor shrinkage when compared to placebo. The field of anti-viral drug development has made dramatic, impressive strides over the past half century, since the discovery of the first-ever medicinal antiviral, Methisazone [7] (for use in the treatment of smallpox and other related viruses), in the 1950s. Methisazone (Figure  3) , an N-methyl derivative of thiosemicarbazone, is active against poxviruses and appears to be effective in the prophylaxis of smallpox and treatment of the complications of vaccination.
Indolin-2-Ones That Have Entered
Clinical Studies
SU5416
SU5416 (Semaxanib) (Figure 4 ) is a synthetic small molecule inhibitor of the tyrosine kinase domain of VEGFR-2. SU5416 is also a potent competitive inhibitor of KIT and less potently the PDGFR (indirectly involved in angiogenesis), but is not directly cytotoxic by itself. Recent work has also suggested that SU5416 may medi- ate some of its effects through inhibition of a second VEGFR [8] . Preclinical xenograft models have confirmed inhibition of tumor growth and a reduction in the number of metastases following treatment with SU5416, as well as a decrease in vascular density in treated tumors as measured by intravital video-microscopy. SU5416 recently underwent phase II clinical trials for its safety and efficacy in patients with recurrent or metastatic head and neck cancer [9] .
SU5614
Karsten et al. [10] disclosed the expression of VEGFR-1/2 and its ligand VEGF in AML cell lines and characterized the inhibitory action of the protein TKI SU5614 ( Figure  5 ) (5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone) on human endothelial and leukemic cells.
The results of this study showed intracellular VEGF expression was detected in 9 of 10 leukemic cell lines. In contrast, VEGFR-1 and VEGFR-2 expression was restricted to 6 and 2 out of 10 cell lines, respectively. Although SU5614 was a effective inhibitor of the VEGFinduced endothelial cell sprouting in vitro, the sensitivity of leukemic cells toward the growth inhibitory activity of the compound was determined by the c-kit, but not by the VEGFR-1/2 expression. SU5614 induced growth arrest and apoptosis in c-kit expressing Kasumi-1, UT-7, and M-07e cells and inhibited the stem cell factor induced tyrosine phosphorylation of c-kit.
SU6668
SU6668 ( Figure 6 ) is a selective inhibitor of the recaptors for VEGFR, PDGFRβ and FGFR1 [11] . SU6668 inhibits the growth of tumor cell lines in vitro and has significant anti-tumor activity in xenografts after daily oral treatment. Laird and co-workers [12] determined the kinase inhibitory profile of SU6668, which is a more water soluble 2-oxindole derivative than SU5416. Using steady state enzyme kinetics with purified recombinant VEGFR-2, they reported that this compound is a competitive inhibitor with respect to ATP.
SU14813
SU14813 (Figure 7) , an orally active indolinone multitargeted TKIs, blocks VEGFR-1, -2, and -3, PDGFR-α, -β, c-kit, and FLT3 at nanomolar concentrations [13] . In vitro, SU14813 inhibited VEGFR-2, PDGFRβ, and FLT3 internal tandem duplication phosphorylation, with cellular IC 50 values of 0.04, 0.02, and 0.05 µmol/l, respecttively, and showed anti-tumor efficacy in tumor xenograft models. Preclinical studies in mice demonstrated a lack of major active metabolites, linear pharmacokinetics and oral bioavailability of 40%. Shem et al. [14] reported a encouraging preclinical data for SU14813 and the clinical implications for its use based on a similar potency to Sunitinib but distinct pharmacokinetic profile, which may favorably affect tolerability and allow greater dosing flexibility, SU14813 warrants further clinical evaluation in human malignancies, both alone and in combination with cytotoxic chemotherapy.
SU11274
SU11274 (Figure 8 ) is an ATP competitive small molecule inhibitor of the catalytic activity of Met which exhibited selectivity for Met enzyme versus a panel of other tyrosine kinases [15] . Chemically SU11274 is a
Recent studies demonstrate that SU11274, a prototypic anti-MET small molecule, is an effective inhibitor of both HGF dependent and independent signaling, which results also from the presence of point mutations. Inhibition of the Met kinase activity by SU11274 led to time and dose dependent reduced cell growth and induced G1 cell cycle arrest and apoptosis. 
SU12662
SU12662 (Figure 9) is an active N-desethyl metabolite of Sunitinib. SU12662 has receptor tyrosine kinase inhibitory profile similar to that of Sunitinib in vitro and has similar plasma protein binding [17] .
SU10944
Neela et al. [19] reported a novel small molecule inhibitor of VEGFR-2, SU10944 (Figure 11 ). This indolinone 2-one derivative is an effective, ATP-competitive inhibitor of VEGFR-2 biochemical activity and is active in the nanomolar range in cellular assays. SU10944 can be administered in vivo by the oral route and achieves sufficient exposure to inhibit nearly all VEGF stimulated ne-
SU5402
SU5402 (Figure 10 
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ovascularization and vascular permeability. Robert disclosed steady state kinetic analysis of SU10944, he found that this compound is a potent ATP competitive inhibittor of VEGFR-2 in vitro with an IC 50 value of 96 nM and a Ki value (a dissociation constant) of 21 nM [20] . They found that SU10944 is a more potent inhibitor of VEGFR-1 when compared with VEGFR-2. However, the compound is not an effective inhibitor of PDGFRβ, KIT or FGFR1.
SU6656
SU6656 (Figure 12 ) is an inhibitor of the Src family of tyrosine kinases [21] , a group of enzymes that regulate many important signaling pathways, including RAS/ MAPK, PI3K/AKT and STAT, and which represent molecular targets for the treatment of various cancers. SU6656 showed cross reactivity with certain other kinases such as the Aurora B kinases, proteins that control cell ploidy and centrosome number. SU6656 can also significantly augment the anti-angiogenic effect of irradiation and may be a useful agent in the treatment of drug resistant cancers.
SU9516
3-substituted indolin-2-ones represent a potent and selec- tive inhibitor for certain RTKs [22] . These small molecules typically act as adenine mimetics that occupy the ATP binding pocket in specific RTKs, with the specificity being governed by the substituents around the indolinone core. Compounds of this class have reached clinical trials for the treatment of several cancers. One such compound is SU9516 (Figure 13) (3-[1-(3H-Imidazol-4 -yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one). From crystal structure of the inhibitor bound to cdk2 and kinetically characterized studies about the inhibition of cdks by SU9516 suggest that this compound could have usefulness as a core molecule for the study of cdk inhibition. Furthermore, information gained from the structural analysis should aid in the development of more potent and specific inhibitors in the future. SU9516 is also reported to inhibit GSK-3 which is involved in normal cell death [23] .
SU4984
SU4984 (Figure 14 Copyright © 2012 SciRes. induced phosphorylation of ERK1 and ERK2 and tyrosine phosphorylation of PDGF and insulin receptors. SU4984 also effective against KIT with juxtamembrane activating mutations [24] .
used, amongst other applications, to synchronize cells, to scrutinize cell cycle phases, to link physiological/biochemical events with kinase activities. More challenging is the development of the application of these pharmacological compounds to multiple areas the scope of which is much wider than initially expected. So far, various kinase inhibitors have been tested in clinical trials resulting in great survival benefit for patients for whom no effective therapy was available. Indolinone a class of compounds displays very promising anti-tumor properties by inhibiting various kinase families. The antikinase activity of the indolinone set of kinase inhibitors was first reported in 1997 by Mohammadi et al. [25] . These small molecules have a low molecular weight and most of them bind to protein kinases competing with ATP for the ATP binding site. Moreover the apparent selectivity of the compound, its potency and favorable
Conclusion
In less than a two decade, the field of chemical inhibitors of receptor tyrosine kinases has seen spectacular developments. Starting from "low throughput screens" the search for selective inhibitors has progressed to massive industrial High Throughput Screens (HTS). It has been accompanied by a large variety of studies ranging from kinase inhibitor interaction at the atomic level (crystallography), molecular modeling, in silico screening, thorough investigation of the inhibitor's selectivity and cellular effects, and pre-clinical studies. These efforts have provided very useful pharmacological tools that can be Figure 15 ). Preclinical as well as preliminary results of clinical trials suggest that this class of agent is promising for cancer treatment and may offer a promising alternative to classical anticancer drugs. Table 1 summarizes the current protein kinase inhibitors in the clinic and in development. 
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